Federal Evidence-Based Psychedelic Research for Mental Health and Trauma Care

Take action and stay informed by becoming an AACPN member today

White House & HHS

In April 2026, the White House issued a major executive order titled “Accelerating Medical Treatments for Serious Mental Illness,” directing federal agencies to accelerate research, clinical testing, and regulatory review of psychedelic therapies.

The order directed:

FDA and DEA to prioritize review pathways for certain psychedelic therapies
ARPA-H to support state-level research initiatives
HHS and VA to increase clinical trial coordination and evidence generation
agencies to explore expanded investigational access pathways for eligible patients

The administration specifically referenced therapies involving ibogaine compounds, PTSD treatment, and veteran mental health.

Veterans Affairs

Veteran mental health has become the single strongest political driver behind federal psychedelic research momentum.

The Department of Veterans Affairs has now funded and launched research involving MDMA-assisted therapy and related behavioral health studies for PTSD, trauma, and alcohol use disorder among veterans. Multiple bipartisan congressional proposals would expand VA research centers and establish “Innovative Therapies Centers of Excellence” focused on psychedelic-assisted treatments.

Advocacy from veterans groups has significantly shifted the political environment around the issue, particularly among Republicans and national security-focused policymakers.

FDA clinical trial

The FDA has increasingly supported clinical research into psychedelic-assisted therapies for conditions such as PTSD, depression, addiction, and treatment-resistant mental illness. Several therapies involving Psilocybin and MDMA have received Breakthrough Therapy designation, allowing for accelerated regulatory review pathways.

The federal government continues to emphasize that these therapies remain experimental and require additional clinical evidence, but the FDA has publicly acknowledged growing interest in their therapeutic potential for difficult-to-treat psychiatric conditions.

ARPA-H & Federal Research

ARPA-H and HHS have begun integrating psychedelic-related research into broader behavioral health innovation initiatives. Recent federal announcements have included research partnerships involving biomarkers, psilocybin trials, and advanced mental health treatment evaluation systems.

The federal government is increasingly treating psychedelic-assisted therapy research as part of a broader mental health innovation and neuroscience modernization effort rather than solely as a drug-policy issue.

Latest on the issue

AACPN Launches Psychedelic Research Initiative to Advance Veteran Mental Health Innovation

The American Alternative Care Policy Network (AACPN) this week launched its Psychedelic Research Initiative to support continued scientific research into emerging therapies that may help address some of America's most difficult mental health challenges. At the center of this effort are veterans. For many veterans, the invisible wounds of service can persist long after they return home. Post-traumatic stress, depression, anxiety, traumatic brain injury, substance-use disorders

AACPN Applauds Connecticut Enactment of Public Act 26-108 Expanding Psychedelic-Assisted Therapy Research

AACPN applauds Connecticut’s enactment of Public Act 26-108, expanding the state’s psychedelic-assisted therapy pilot program and supporting continued clinical research involving MDMA and psilocybin therapies for veterans, first responders, trauma survivors, and individuals living with treatment-resistant mental health conditions.

Veteran participating in a clinical mental health research session as the U.S. Department of Veterans Affairs launches a study evaluating MDMA-assisted therapy for PTSD and alcohol use disorder among veterans and trauma survivors.

AACPN Statement on VA MDMA-Assisted Therapy Trial

AACPN welcomes the U.S. Department of Veterans Affairs’ launch of a clinical trial evaluating MDMA-assisted therapy for veterans living with PTSD and alcohol use disorder. The organization says rigorous scientific research is essential to understanding whether emerging therapies can safely and effectively support veterans and other trauma survivors facing complex behavioral health challenges.